Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

NCT00387764 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: pazopanib

Sponsor

GlaxoSmithKline